Clinical trials: Azithromycin
Childhood Mortality
Community Health Azithromycin Trial in Burkina Faso
An estimated 7.7 million pre-school aged children die each year, the majority from infectious diseases. Mass azithromycin distributions for trachoma may have the unintended benefit of reducing childhood mortality.
- Trial name
- CHAT (NCT03676764)
- Testing
- Azithromycin
- Where
- Burkina Faso
- Volunteers
- 77,664 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Bronchopulmonary Dysplasia
TINN2: Treat Infection in NeoNates 2
The aim of the TINN2 study is to evaluate the efficacy of azithromycin in prevention of bronchopulmonary dysplasia in preterm neonates.
- Trial name
- TINN2 (NCT02282176)
- Testing
- Azithromycin
- Where
- 16 sites in Belgium, France and 7 more
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Trachoma, Yaws
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF.
- Conditions
- Trachoma, Yaws, Lymphatic Filariases, Scabies
- Trial name
- NCT03676140
- Testing
- Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1
- Where
- Papua New Guinea
- Volunteers
- 20,000 people
- Sponsor
- Lihir Medical Centre
Trachoma
Azithromycin in Control of Trachoma II
Trachoma is the world's leading cause of preventable blindness. This disease, caused by Chlamydia trachomatis, is endemic in many parts of the developing world.
- Trial name
- NCT00286026
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco